I
n their recently published randomized, controlled trial (RCT), Davidson et al. (1) found no significant effect of highdose vitamin D supplementation on insulin secretion, insulin sensitivity, and incident diabetes. Their RCT is of particular importance because the researchers included subjects with diabetes and vitamin D insufficiency, i.e., a cohort that according to previous observational studies should most likely benefit from vitamin D treatment (2) . Although the findings of Davidson et al. clearly show no relevant effect of vitamin D supplementation, it must also be underlined that their mean dose of 88,865 IU per week, corresponding to a daily dose of 12,695 IU, was safe without causing hypercalcemia or hypercalciuria. These are crucial new data regarding vitamin D safety. In this context, there is an ongoing debate on tolerable upper intake levels for vitamin D, which are 4,000 IU according to the Institute of Medicine and 10,000 IU according to The Endocrine Society (3, 4 ] nmol/L) are optimal for multiple health outcomes including mortality, with some studies even reporting a U-shaped association (5) . Therefore, and taking into account the increasing number of negative RCT results, which suggest that vitamin D is not a wonder drug for everyone, it will be important for future research to 1) focus on vitamin D-sensitive individuals, e.g., vitamin D-deficient individuals, and 2) use vitamin D doses to achieve optimal 25(OH)D levels. Several vitamin D hopes for outcomes with relevance for diabetic patients such as blood pressure or cardiovascular events still remain to be further evaluated in such RCTs. While waiting for these trial results, we want to note finally that, regardless of the current disappointing data on vitamin D and glycemic control, diabetic patients are prone to osteoporosis and fractures, for which vitamin D supplementation is indeed an established treatment (3, 4 
